Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, Inc., is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib.
Back to dashboard
Company Information
About this company
Key people
Anand K. Parikh
Chairman of the Board, President, Chief Executive Officer
Phillip B. Donenberg
Independent Director
Bob Holmen
Independent Director
Brian Stephenson
Chief Financial Officer and Principal Financial Officer
Josiah Craver
Senior Vice President - Finance, Principal Accounting Officer
Oliver Maddocks
Chief Scientific Officer
Christopher W. Gerry
General Counsel, Corporate Secretary
Debbie Chirnomas
Chief Medical Officer
Stephen M. Hahn
Director
Saira Ramasastry
Director
Karen Vousden
Director
Click to see more
Key facts
- Shares in issue25.84m
- EPICFTH
- ISINUS81728A2078
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$485.80m
- Employees29
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.